CiLostAzol for preventing recurrent stroke in Africa (CLARITY-Africa)
Official title: CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-Africa)
Funded at Northern California Institute/res/edu · NIH-11419766 · Data updated 2026-11-12
A new study tests whether adding cilostazol to standard therapy can lower the risk of another stroke for people in sub-Saharan Africa.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $78,953 |
| NIH project number | 5R01NS139346-03 |
| Project ID | NIH-11419766 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults in sub-Saharan Africa who have survived a previous stroke and are candidates for secondary prevention therapy.
✕Less likely to help
Patients with contraindications to cilostazol or a high bleeding risk may not benefit.
What this research studies
This project aims to see if cilostazol, taken twice daily with aspirin or clopidogrel, reduces recurrent stroke and heart-related problems in stroke survivors in Africa. It uses a hybrid design to evaluate safety and effectiveness in a resource-limited setting while building local stroke research capacity. The study focuses on real-world use among adults in sub-Saharan Africa who have already had a stroke, with follow-up to monitor outcomes and safety. If successful, it could provide a cost-effective option that improves long-term survival for a population with high stroke burden.
Why it matters
Potential benefit: If successful, patients could have a safer, more effective option to prevent a second stroke and related complications, potentially improving long-term survival.
How similar studies have gone: Previous data in Asian populations suggest cilostazol reduces major cardiovascular events when added to standard therapy.
Where this research is happening
-
Northern California Institute/res/edu
San Francisco, United States Active
Researchers
- Principal investigator: Ovbiagele, Bruce — Northern California Institute/res/edu
- Study coordinator: Ovbiagele, Bruce
Related research
Other NIH-funded projects on the same topics.
-
Stroke prevention with hydroxyurea for children with sickle cell anemia in Nigeria
A multinational, patient-facing study tests whether hydroxyurea can safely prevent first strokes in Nigerian children with sickle cell anemia.
-
Music-powered tools to boost blood pressure and stroke prevention for Nigerian youth and their older caregivers
This project uses popular music to help Nigerian youths and their older family members start and stick to blood pressure and stroke prevention habits.
-
Determinants of Post-Stroke Cognitive Outcomes and Vascular Effects on Recovery
A large, multi-site effort aims to understand why some stroke survivors develop long-term cognitive problems and dementia, and how vascular health and pre-existing brain changes influence recovery.
-
LRP1 controls NSC movement and stroke recovery
This NIH grant studies how a brain receptor called LRP1 helps neural stem cells move to stroke injuries and support recovery in adults.
-
BBB Dysfunction after Stroke and Risk for Dementia
A study at Stanford will look at whether inflammation after a stroke leads to leaky blood vessels and later dementia, by following stroke survivors and comparing them with people without stroke.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.